Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D DeVore

Showing results (21-30 of 339) with videos related to

Pageof 34
Sort By:
Journal of Cardiac Failure|October 10, 2021
HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an EpidemicAdam D Devore, Kelly H Schlendorf
JACC. Heart Failure|September 10, 2018
Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?Adam D DeVore, Jennifer B Green
European Journal of Heart Failure|June 16, 2021
Can we prevent infections in patients with left ventricular assist devices?Karen F Rosario, Adam D DeVore
Journal of the American College of Cardiology|July 26, 2023
A Global Challenge and a Global Opportunity for the Heart Failure CommunityAdam D DeVore, Larry A Allen
Journal of Cardiac Failure|February 19, 2026
Antibody-Mediated Rejection (without the antibodies) in Heart TransplantationJoshua A Rushakoff, Adam D DeVore
Cardiology Clinics|October 9, 2022
Pharmacologic Therapy for Heart Failure with Preserved Ejection FractionAnthony E Peters, Adam D DeVore
Evidence-Based Medicine|March 19, 2014
Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failureAdrian F Hernandez, Adam D DeVore
JACC. Heart Failure|August 7, 2018
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving HopeAdam D DeVore, Jonathan P Piccini
JACC. Heart Failure|August 18, 2020
The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart FailureStephen J Greene, Adam D DeVore
JACC. Heart Failure|September 16, 2019
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart FailureAdam D DeVore, Sana M Al-Khatib
Pageof 34

Showing results (21-30 of 339) with videos related to

Sort By:
Pageof 34
Journal of Cardiac Failure|October 10, 2021
HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an EpidemicAdam D Devore, Kelly H Schlendorf
JACC. Heart Failure|September 10, 2018
Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?Adam D DeVore, Jennifer B Green
European Journal of Heart Failure|June 16, 2021
Can we prevent infections in patients with left ventricular assist devices?Karen F Rosario, Adam D DeVore
Journal of the American College of Cardiology|July 26, 2023
A Global Challenge and a Global Opportunity for the Heart Failure CommunityAdam D DeVore, Larry A Allen
Journal of Cardiac Failure|February 19, 2026
Antibody-Mediated Rejection (without the antibodies) in Heart TransplantationJoshua A Rushakoff, Adam D DeVore
Cardiology Clinics|October 9, 2022
Pharmacologic Therapy for Heart Failure with Preserved Ejection FractionAnthony E Peters, Adam D DeVore
Evidence-Based Medicine|March 19, 2014
Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failureAdrian F Hernandez, Adam D DeVore
JACC. Heart Failure|August 7, 2018
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving HopeAdam D DeVore, Jonathan P Piccini
JACC. Heart Failure|August 18, 2020
The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart FailureStephen J Greene, Adam D DeVore
JACC. Heart Failure|September 16, 2019
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart FailureAdam D DeVore, Sana M Al-Khatib
Pageof 34